Abstract
541 Background: Although cancer and its treatments are well-recognized risk factors for thromboembolism (TE), such as venous and pulmonary TE, there are very few data of the incidence of cancer associated TE in the Asian population. So we conducted a retrospective cohort study to investigate the TE incidence of gastrointestinal tract cancer (GTC) patients (pts) receiving chemotherapy in a Japanese community hospital’s daily practice setting. Methods: All the patients received chemotherapy for GTC in our hospital from January 2008 to May 2015 were identified through medical records review extracted by our hospital data warehouse. We analyzed the incidences of TE by reviewing all the reports of contrast-enhanced computed tomography performed on each patient during chemotherapy and identified the association between several clinicopathological factors and TE incidence using chi-square tests and logistic regression. Results: Five hundred fourteen Japanese GTC pts were analyzed on this study. Patient characteristics were as follows; male/female 317/197, median age 69.1 (range 21.1 - 89.1), Gastric (GC)/Colorectal cancer (CRC) pts 213/301, non-adjuvant (non-Adj)/adjuvant (Adj) setting 314/200, tumor-bearing (TB)/non-TB pts 344/170, multiple primary (MP)/single primary (SP) pts 29/485. The incident rate with TE in GC and CRC pts was 10.3 % (n = 22) and 16.6 % (n = 50), respectively. In relation to the status of malignancy, the incidence of TE was 16.6 % (n = 52) and 10.0 % (n = 20) in non-Adj and Adj setting (p = 0.0367), 16.9 % (n = 59) and 7.9 % (n = 13) in TB and non-TB pts (p = 0.007), 31.0 % (n = 9) and 13.0 % (n = 63) in MP and SP pts (p = 0.007), respectively. Conclusions: We found that there were significantly higher incidences of TE in non-Adj, TB, and MP compared with Adj, non-TB, and SP pts, respectively. Although the ethnic differences of the TE incidence rate between Caucasian and Asian population were reported, the incidence of Asian population received cancer chemotherapy remains unclear yet. So further accumulation of data are necessary to establish a Guideline for Asian to prevent and manage TE occurred during cancer chemotherapy such as ESMO or ASCO guidelines. Clinical trial information: UMIN000018912.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
